Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 9419453 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| we performed a phase i clinical trial assessing the administration of autologous dc pulsed with hla-a0201-specific prostate-specific membrane antigen (psma) for the treatment of 51 men with hormone-refractory prostate cancer. | |||||||
| 9559839 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | prostate cancer | Japanese | NA | NA | unclassified | |
| this study was conducted to clarify the clinical features and incidence of the human leukocyte antigen (hla) in familial prostate cancer in patients seen at hospitals in japan. | |||||||
| 9559839 | HLA-CLASS II (HLA CLASS II) | prostate cancer | Japanese | NA | NA | unclassified | |
| in addition, hla class ii gene typing was performed in 17 patients from 11 families with familial prostate cancer (group f') and their healthy family members (15 males and 25 females). | |||||||
| 9559839 | HLA (HLA) | prostate cancer | Japanese | NA | NA | positive+negation | |
| there were no significant differences in clinical parameters between group f and group s, except that the age at diagnosis was lower in group f patients, and that the frequency of several hla class 11 alleles was significantly higher in patients with prostate cancer. | |||||||
| 9568678 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| report of immune monitoring of prostate cancer patients undergoing t-cell therapy using dendritic cells pulsed with hla-a2-specific peptides from prostate-specific membrane antigen (psma). | |||||||
| 9650914 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| a phase i trial involving patients with advanced prostate cancer was conducted to assess the safe administration of dendritic cells (dc) and hla-a0201-specific prostate-specific membrane antigen (psma) peptides (psm-p1 or -p2). | |||||||
| 9973112 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| infusion of dendritic cells pulsed with hla-a2-specific prostate-specific membrane antigen peptides: a phase ii prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. | |||||||
| 10344219 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| recombinant human granulocyte-macrophage colony-stimulating factor (gm-csf; leukine [sargramostim], immunex corp., seattle, wa) was administered to a subgroup of 44 patients in a phase ii clinical trial for prostate cancer using dc pulsed with hla-a2-specific prostate-specific membrane antigen (psma) peptides. | |||||||
| 12735843 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| our approach to prostate cancer immunotherapy involves two components dendritic cells as antigen-presenting cells; and the antigen used to target t-cell attack, hla-a0201-associated peptides from prostate specific membrane antigen (psma). | |||||||
| 12841872 | HLA-A*24 | prostate cancer | NA | NA | NA | only_studied | |
| identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in hla-a24+ prostate cancer patients. | |||||||
Copyright 2024